Xywav
| Combination of | |
|---|---|
| Calcium oxybate | Central nervous system depressant |
| Magnesium oxybate | Central nervous system depressant |
| Potassium oxybate | Central nervous system depressant |
| Sodium oxybate | Central nervous system depressant |
| Clinical data | |
| Trade names | Xywav |
| Other names | JZP-258 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a621001 |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Xywav (calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate) is a fixed-dose combination medication used to treat cataplexy or excessive daytime sleepiness. It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate. It is a central nervous system (CNS) depressant and it is taken by mouth.
It is manufactured by Jazz Pharmaceuticals and was approved for medical use in the United States in July 2020.